KLRS
NASDAQ HealthcareKalaris Therapeutics, Inc. - Common Stock
Biotechnology
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), which is in Phase 1b/2, as well as for the treatment of other exudative and neovascular retinal diseases. Kalaris Therapeutics, Inc. was formerly known as Theia Therapeutics, Inc. and changed its name to Kalaris Therapeutics, Inc. in May 2024. The company was founded in 2019 and is headquartered in Berkeley Heights, New Jersey.
�� 市场数据
| 价格 | $6.32 |
|---|---|
| 成交量 | 105,975 |
| 市值 | 144.91M |
| RSI（14日） | 62.6 |
| 200日均线 | $6.17 |
| 50日均线 | $8.09 |
| 52周最高 | $11.88 |
| 52周最低 | $2.14 |
| Forward P/E | -4.17 |
| Price / Book | 1.84 |
🎯 投资策略评分
KLRS 在各投资策略中的评分。分数越高，越符合该策略目标。
🔍 策略解读
最佳匹配： 🔪 Falling Knife (66/100) — 此策略 逆向投资（超卖 + 低于移动均线）.
评分最低的策略： 🐋 Institutional Whale (2/100). 单一评分不构成买入或卖出信号 — 请结合多种视角综合判断。 了解如何解读这些评分 →
📚 了解更多
在文本中查找 KLRS in your text
粘贴任何文章、记录或帖子 — 工具将提取 KLRS 以及每一个其他隐藏的股票代码。
免责声明：本数据仅供教育和娱乐用途，不构成金融建议。市场数据可能存在延迟。在做出投资决策之前，请始终进行自己的研究。
数据最后更新： 2026-04-17.